<DOC>
	<DOCNO>NCT02556606</DOCNO>
	<brief_summary>The purpose study examine effectiveness single infusion ketamine ( KET ) , determine dose optimal last long , learn ketamine work body brain person late-life treatment resistant depression .</brief_summary>
	<brief_title>Ketamine Treatment Resistant Late-Life Depression</brief_title>
	<detailed_description>Primary Aim : To identify evaluate durability benefit best perform 3 sub-anesthetic dos single ketamine ( 0.1 mg/kg , 0.25 mg/kg , 0.50 mg/kg ) midazolam ( MID ) ( 0.03 mg/kg ) infusion 72 Veterans Late-Life Treatment Resistant Depression ( LL-TRD ) . Hypothesis 1 : durability benefit single KET 0.5 mg/kg infusion superior ( 0.1 mg/kg , 0.25 mg/kg , MID 0.03 mg/kg ) time relapse measure repeat measurement use Montgomery-Asberg Depression Rating Scale ( MADRS ) four-week , post-infusion follow-up . Secondary Aim : To evaluate compare antidepressant efficacy best perform 3 sub-anesthetic dos single KET ( 0.1 mg/kg , 0.25 mg/kg , 0.50 mg/kg ) MID ( 0.03 mg/kg ) infusion vet LL-TRD , use triple blind ( patient , rater , anesthesiologist ) Bayesian adaptive randomization design . Hypothesis 2 : single KET 0.5 mg/kg infusion superior single infusion KET ( 0.1 mg/kg ) , KET ( 0.25 mg/kg ) , MID 0.03 mg/kg ) measure proportion participant demonstrate &gt; 50 % reduction MADRS score 72-hour post-infusion . Tertiary Aim : To evaluate immediate longer-term safety tolerability effective KET infusion ( 0.5 mg/kg ) relative MID ( 0.03 mg/kg ) vet LL-TRD . Hypothesis 3 : KET infusion effective dose ( 0.5 mg/kg ) safe well tolerate compare MID , assess psychoactive general side effect rating scale 4 week post study infusion . Exploratory Aims : 1 . To measure effect effective dose KET ( 0.50 mg/kg ) relative MID ( 0.03 mg/kg ) neurocognitive performance . 2 . To measure effect effective dose KET ( 0.50 mg/kg ) relative MID ( 0.03 mg/kg ) peripheral biomarkers cellular plasticity inflammation . 3 . To measure effect effective dose KET ( 0.50 mg/kg ) relative MID ( 0.03 mg/kg ) resting-state quantitative electroencephalography .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Male female patient , 55 year age , Participants must fulfill DSM 5 criterion Major Depressive Episode ( Unipolar ) , base structure diagnostic interview , DSM 5 M.I.N.I . 7.0 Participants must history least one previous episode depression prior current episode ( recurrent MDD ) chronic MDD ( least two year ' duration ) , Participants respond two adequate trial FDAapproved antidepressant , determine Antidepressant Treatment Response Questionnaire ( ATRQ ) criterion . Participants must score 14 great Quick Inventory Depressive SymptomatologySelf Report ( QIDSSR ) , score 27 Montgomery Asberg Depression Rating Scale ( MADRS ) , Each participant must level understanding sufficient agree test examination require protocol must sign informed consent document . Patients currently fluoxetine , History schizophrenia , schizoaffective disorder psychotic disorder , bipolar disorder , Documented history psychotic disorder firstdegree relative , Current diagnosis obsessivecompulsive disorder ( OCD ) eat disorder [ bulimia nervosa anorexia nervosa ] , Alcohol substance use [ except nicotine ] within precede 6 month , Patients clinically significant personality disorder would , investigator 's judgment , preclude safe study participation , Patients judge serious imminent suicidal homicidal risk , Serious , unstable medical illness include respiratory [ obstructive sleep apnea , history difficulty airway management previous anesthetic ] , cardiovascular [ include ischemic heart disease uncontrolled hypertension ] , neurologic [ include history severe head injury ] , For study entry , patient must reasonable medical candidate ketamine midazolam infusion , determine boardcertified physician coinvestigator study Screening , Clinically significant abnormal finding laboratory parameter [ include urine toxicology screen drug abuse ] , physical examination , ECG , Hypertension ( systolic BP &gt; 160 mm Hg diastolic BP &gt; 90 mm Hg ) , Patients one 11 seizure without clear resolve etiology , Patients start hormonal treatment ( e.g. , estrogen ) 3 month prior Screening , Past intolerance hypersensitivity ketamine , history recreational use phencyclidine ( PCP ) ketamine , Past intolerance hypersensitivity midazolam , Agerelated cognitive decline mild dementia suggest score &lt; 25 MiniMental State Examination ( MMSE ) Screening , Patients take medication know activity NmethylDaspartate receptor ( NMDA ) AMPA glutamate receptor [ e.g. , riluzole , amantadine , lamotrigine , memantine , topiramate , dextromethorphan , Dcycloserine ] , muopioid receptor , Patients take follow medication : St John 's Wort , theophylline , tramadol , metrizamide , Patients demonstrate &gt; 25 % decrease depressive symptom reflect QIDSSR score Screening Randomization , Patients receive electroconvulsive therapy ( ECT ) past 6 month prior Screening , Patients currently receive treatment vagus nerve stimulation ( VNS ) repetitive transcranial stimulation ( rTMS ) .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ketamine</keyword>
	<keyword>depression</keyword>
	<keyword>treatment resistant</keyword>
	<keyword>treatment resistant depression</keyword>
	<keyword>late life depression</keyword>
	<keyword>depression elderly</keyword>
	<keyword>geriatric depression</keyword>
</DOC>